STEK 最新10-Q变化
将 STEK 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-06-22 与上一份 10-Q · 2025-11-19
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +33 | −44 | ~3 | 11 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 法律诉讼 | 文字有新增/删除 | +2 | −5 | 0 | 0 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-06-22
Globe Net Wireless Corp was incorporated in the State of Nevada, USA on September 4, 2009 with ticker symbol “GNTW”. On August 19, 2021, Stemtech Corporation (“Stemtech”), a (Delaware corporation), entered into a Merger Agreement (the “Merger Agreement”) with Globe Net Wireless Corp. (“Globe Net” or…
Stemtech’s patented, advanced Stem Cell Nutrition formulations are one-of-a-kind natural products designed to help support the three most important aspects of stem cell physiology found in our RCM System: 1) Releasing the body’s own stem cells slowing down the bodies aging process; 2) their Circulat…
In December 2022, our new Cellect One® Rapid Renew Stem Cell Peptide Night Cream. The Night Cream is a Stemtech proprietary formula containing an FDA patented ingredient, Red Oak Bark, which enables deep penetration to promote good skin health. In 2025, we introduced Cellect One® Shield: HOCL (Hypoc…
While sales of products obviously create the cash flow, our real business model is not just “sales”, but lateral penetration. We do this through our IBPs - “Independent Business Partners” Sales Force, and we invest much energy in growing our IBPs. Post funding, Stemtech is projecting the addition of…
During the three months ended March 31, 2026 and 2025, net sales were $462,957 and $868,046, respectively, representing a decrease of $405,089. The decline in net sales was primarily attributable to a continued reduction in available inventory across certain key product lines, which constrained the …
相对上期删除的文字 · 来源:10-Q · 2025-11-19
Stemtech Corporation was incorporated in Nevada on March 4, 2009, and became a publicly traded entity after its registration statement on Form S-1 was declared effective on May 15, 2013. On August 19, 2021, Stemtech acquired 100% of Stemtech Corporation, resulting in the issuance of 37,060,000 share…
Stemtech has pioneered a unique category of Stem Cell Nutrition, offering natural, patented dietary supplements that support the three key aspects of stem cell physiology: the release, circulation, and migration of adult stem cells. Our products are formulated with botanicals and other clinically do…
· Stemrelease3™ – the release of the body’s own adult stem cells
· StemFlo Advanced® - circulation of adult stem cells through the bloodstream
· MigraStem® - migration of stem cells from the bloodstream into the tissues in need of support
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-06-22
On August 6, 2019, the former CEO prior to the Company’s Bankruptcy, filed a lawsuit against the Company’s subsidiary Stemtech HealthSciences, alleging unpaid salary and vacation time dating to a period predating the Company’s current management team taking control in 2018. Plaintiff’s claim is in t…
In the opinion of management, the resolution of this matter, if any, will not have a material adverse impact on the Company’s consolidated financial position or consolidated results of operations.
相对上期删除的文字 · 来源:10-Q · 2025-11-19
The former CEO of Stemtech HealthSciences Corp. has claimed approximately $267,000 in unpaid compensation relating to periods before current management took over in 2018. The Company disputes the claim and has filed a counterclaim. The case is ongoing.
Based on management’s assessment, a loss of $267,000 is considered probable, and this amount has been fully accrued as of September 30, 2025. The Company cannot estimate any additional loss at this time.
Some lenders under the Company’s Merchant Cash Advance (“MCA”) agreements have filed legal actions alleging defaults and demanding repayment. These matters are still at an early stage.
The Company continues to carry the entire MCA balances as liabilities. Management believes that any loss above the recorded amounts is reasonably possible, but the amount of any additional loss cannot be estimated at this time. The Company intends to defend these claims.
These matters may increase legal expenses or accelerate payments, which could affect liquidity. Management is taking steps to address these uncertainties through planned financing and cost controls.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议